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Abstract
Background: The pathogenesis of salivary gland carcinomas is very complex and prognostic markers are difficult
to find in these carcinomas of which the different subtypes have varying malignant potential. The study was
conducted to examine the cellular distribution of maspin and MCM2 in salivary gland carcinomas and their value
to predict lymph node metastasis.
Materials and methods: Fifty three paraffin blocks of different lesions (15 muco-epidermoid carcinoma, 14
adenoid cystic carcinoma, 3 epi-myoepithelial carcinoma, 5 salivary duct carcinoma, 5 malignant pleomorphic
adenoma, 6 polymorphous low grade adenocarcinoma and 5 acinic cell carcinoma) were prepared for
immunohistochemical staining with maspin and MCM2 antibodies. ANOVA and Pearson correlation tests were used
for the statistical analysis of the results.
Results: All salivary gland carcinomas express maspin and MCM2 with variable cellular localization. There was a
significant difference in the expression of each antibody between mucoepidermoid carcinoma, adenoid cystic
carcinoma and polymorphous low grade adenocarcinoma. No association was found between examined markers
and lymph node metastasis.
Conclusions: Salivary gland carcinomas express maspin and MCM2 with variable levels and cellular localization,
consisting important markers of biological behavior in these tumors. The level of MCM2 expression can be used in
the differential diagnosis of adenoid cystic carcinoma and polymorphous low grade adenocarcinoma. Further study
with large sample size is recommended to assess their value in prediction of lymph node metastasis.
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Introduction
Salivary gland neoplasms which comprise about 5% of
head and neck cancers are a morphologically and clini-
cally diverse group of lesions and may present consider-
able diagnostic challenge to the pathologist [1]. The most
frequent salivary gland carcinoma types are mucoepider-
moid carcinoma, adenoid cystic carcinoma, acinic cell
carcinoma, malignant pleomorphic adenoma and salivary
duct carcinoma [2].
Mammary Serine Protease Inhibitor (maspin) belongs to
the serine protease inhibitor (serpin) family [3,4], which
comprises a large protein family with diverse biological
functions [5]. There is a controversy about maspin
protease inhibition; Sheng et al [6] stated that maspin has
protease inhibitory activity. On the contrary, Bass et al [7]
reported that maspin has no protease inhibitory
properties.
Maspin expression has been demonstrated in multiple
tissues including epithelium of the breast, prostate, lung
and in stromal cells of the cornea [8-10]. Maspin demon-
strates broad localization patterns [5], in mammary epithe-
lial cells, maspin localizes primarily to the cytoplasm, but
can also localize to the nucleus, and the cell surface [11].
One of the first regulatory mechanisms identified for
maspin involved p53 signaling. The regulation of maspin
by p53 could explain the role of p53 in cell invasion and
metastasis and hypothesizes that cancer cells expressing
mutant p53 would be more likely to metastasize, in part
due to the inability to upregulate the maspin gene [5]. In
addition, increased maspin was associated with an increase
in apoptosis and a reduction in cell invasion. This effect
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any medium, provided the original work is properly cited.was blocked by the addition of a maspin-blocking antibody
[12].
Recent study has also established a role for the com-
mon breast cancer drug Tamoxifen (TAM) in regulating
the expression of maspin [5]. The clinical efficacy of
TAM has been attributed to growth arrest and induction
of apoptosis in breast cancer cells. TAM was shown to
induce maspin expression in vitro and in situ [13]. Also,
it was suggested that maspin has an inhibitory effect on
tumor induced angiogenesis [14], cell motility, invasion
and metastasis [15]. Extensive studies have been underta-
ken to determine the mechanisms employed by maspin
to produce its anti-metastatic effects. One line of evi-
dence suggests that maspin regulates cell invasion by
altering the integrin profile of the cell [5]. In support of a
cell surface event, it has been reported that cell surface-
associated maspin is primarily responsible for its anti-
invasive properties [16].
Several reports indicated that maspin can function as
an inhibitor of angiogenesis. Both rMaspin and secreted
maspin can impede the migration of cultured endothelial
cells toward bFGF and VEGF which act as important
chemo-attractants during angiogenesis. Also, maspin was
shown to effectively block neovascularization and reduce
the density of the neoplasm-associated microvessels in
vivo [17,18]. Solomon et al [19] reported that neoplasms
with both cytoplasmic and nuclear maspin expression
had lower VEGF and cyclooxygenase-2 (COX-2) expres-
sion than neoplasms with cytoplasmic maspin expression
only, so suppression of VEGF by maspin may thus occur
through a COX-2 mediated pathway.
In addition to its anti-angiogenic properties, maspin has
also been implicated in apoptosis [5]. It has been demon-
strated that maspin sensitizes breast cancer cells to staur-
osporine (STS)-induced apoptosis [20]. Staurosporine is a
synthetic chemical known to induce apoptosis via an
intrinsic pathway [21]. The apoptotic effect of maspin
appears to be tumor-specific since normal epithelial cells
that express maspin at a high level are not sensitized to
drug-induced apoptosis [22].
The ubiquitous localization of maspin (cytoplasmic,
nuclear, cell surface-associated, secreted) suggests that
maspin may be involved in multiple pathways and pro-
cesses. Loss of maspin has been associated with poor prog-
nosis in various malignant neoplasms like ovarian cancer,
oral squamous cell carcinoma, lung and prostate cancer
[23-25].
The MCM (minichromosome maintance) proteins
identify a group of ten conserved factors functioning in
the replication of the genomeo fe u k a r y o t i co r g a n i s m s
[26]. Among these, MCM2-7 proteins are related to each
other and form a complex implicated at the initiation
step of DNA synthesis. MCM2-7 act as licensing factors
for DNA replication to ensure that the genome is repli-
cated only once in each cell cycle [26,27].
Since MCM activity is essential for DNA replication in
dividing cells and is lost in quiescence [28], MCMs are
obvious markers for proliferation [26]. Molecular studies
suggested that increased levels of MCMs mark not only
proliferative malignant cells, but also precancerous cells
and the potential for recurrence [29,30]. In breast cancers,
increasing neoplasm grade is associated with increased
MCM2 expression [31]. Thus, they may prove to be effec-
tive markers for diagnosis of neoplasms [26].
Several studies reported that MCM2 and Ki-67 are both
markers of cellular proliferation and required for cell cycle
progression [32]. They showed that anti-MCM2 antibody
stained a larger number of cells than anti Ki-67, suggesting
that Ki-67 may be expressed during a shorter interval of
the cell cycle than MCM2 [33]. MCM2 is present through-
out the four phases of cell cycle [31], while Ki-67 is predo-
minantly expressed during S, G2 and M phases. The
present study aimed to evaluate the expression of maspin
and MCM2 in salivary gland carcinomas and their value
to predict lymph node metastasis.
Materials and methods
The material of this study consisted of 53 formalin-fixed,
paraffin-embedded specimens of malignant salivary gland
neoplasms, all collected from the archives of the General
Pathology Department, Faculty of Medicine, Ain Shams
University and National Cancer Institute, Cairo University.
Fifteen cases of mucoepidermoid carcinoma (MEC), 10
of which were diagnosed as high grade and the other 5
cases as low grade, 14 cases of adenoid cystic carcinoma
(ADCC), 5 cases of salivary duct carcinoma (SDC), 3 cases
of epi-myoepithelial carcinoma (EMC), 5 cases of malig-
nant pleomorphic adenoma (MPA), 6 cases of polymor-
phous low-grade adenocarcinoma (PLGA) and 5 cases of
acinic cell carcinoma (ACC). Clinical information about
lymph node metastasis was obtained from patients’ medi-
cal records (summary of cases is displayed in table 1). For
all specimens five micrometer thick sections were pre-
pared and stained with hematoxylin and eosin to confirm
the diagnosis.
In summary, immunohistochemical staining is per-
formed as follows: the tissues were deparaffinized in xylene
and hydrated through graded alcohol and washed with tap
water. Based on the manufacturers’ recommendation, the
slides were transferred for antigen retrieval. The slides
were washed with phosphate buffer and separately incu-
bated with maspin (Visionbiosystems Novocastra™
Laboratories, Ltd, United Kingdom) diluted at a ratio of
1:30 and MCM2 (Lab Vision Corporation, USA) diluted at
a ratio of 1:50 over-night. The slides were then washed
again in PBS and incubated with biotinylated antibody for
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slides were incubated with peroxidase labeled streptavidin
for 30 minutes and washed in PBS. Subsequently, DAB
chromogen was applied for antibody staining (brown).
The samples were then allowed to react with Mayer’s
hematoxylin for 5 minutes, dehydrated and covered with
cover glass.
For each positive section, 6 microscopic fields showing
highest immunopositivity were selected and photomicro-
graphs were captured at original magnification 40×. This
was performed using a digital camera (C5060, Olympus,
Japan) mounted by a C-mount to a light microscope
(BX60, Olympus, Japan). All the steps for immunohisto-
chemical evaluation were carried out using image analysis
software (Image J, 1.41a, NIH, USA). The area fraction
(AF) of the positive cells was calculated automatically. The
area fraction represented the percentage of immunoposi-
tive area to the total area of the microscopic field. The col-
lected data was tabulated in an excel sheet and statistically
analyzed using SPSS 15.
Results
All cases of MEC demonstrated maspin immunoreactivity.
Most of the epidermoid cells in the cases diagnosed as
high grade were negative for maspin, with a few positive
cells in which the reaction was cytoplasmic. The mucous-
secreting cells showed membranous staining. Low grade
MEC showed more positive cells with nuclear and cyto-
plasmic staining of the epidermoid cells (Figure 1a). Con-
cerning MCM2, most of the epidermoid cells revealed
cytoplasmic staining in high grade cases (Figure 2a), while
in low grade cases, little number of epidermoid cells were
positive.
In ADCC, 12 cases of cribriform pattern demonstrated
cytoplasmic maspin and MCM2 staining (Figure 1b, 2b).
Two cases of solid pattern were negative for maspin but
revealed cytoplasmic reaction for MCM2. Myoepithelial
cells were negative for both antibodies.
In EMC, the neoplastic cells demonstrated cytoplasmic
and nuclear (either the whole nucleus or confined only to
the nuclear membrane) maspin staining and cytoplasmic
MCM2 staining (Figure 1c, 2c). Few neoplastic cells were
negative for maspin and MCM2.
In SDC, cases with solid and papillary pattern showed
cytoplasmic maspin and MCM2 reaction (Figure 1d, 2d).
In cribriform pattern with comedo necrosis, little nuclear
and mainly cytoplasmic maspin reaction was detected,
while MCM2 revealed cytoplasmic reaction only.
In MPA, all cases revealed nuclear and cytoplasmic mas-
pin and MCM2 reaction in epithelial and some myoe-
pithelial cells (Figure 1e, 2e), but in PLGA, there was
cytoplasmic reaction for both antibodies in neoplastic cells
arranged in cribriform and cystic pattern (Figure 1f, 2f). In
ACC, one case of clear cell variant demonstrated membra-
nous maspin and MCM2 reaction, while the remaining
cases showed nuclear and cytoplasmic reaction for both
antibodies (Figure 1g, 2g).
Statistically, ANOVA test revealed significant difference
in the expression of both markers between MEC, ADCC
and PLGA (P value = 0.000) (table 2, 3). Results of Post
Hoc test for maspin and MCM2 expression are shown in
table 4 and 5 respectively. Pearson’s correlation analysis
revealed no significant correlation between both maspin
or MCM2 expression and lymph node metastasis.
Discussion
Salivary gland neoplasms are a relatively rare and mor-
phologically diverse group of lesions. A diagnosis based
on hematoxylin and eosin stained sections remains the
gold standard in salivary gland pathology [1].
Several studies were performed to detect the expression
of maspin protein in different malignant neoplasms such
as ovarian carcinoma, oral squamous cell carcinoma, pul-
monary adenocarcinoma and prostate carcinoma to clarify
its role in malignancy. Most researchers found that the
increased maspin expression does correlate with better
prognosis in these neoplasms [19,23-25].
Recent studies have proposed that MCM proteins may
be sensitive proliferation markers and may serve as novel
biomarkers for prognostication and diagnosis of various
Table 1 Types of cases and association with lymph node metastasis of the selected cases
Malignant Salivary
Gland Neoplasms
Total Number of cases Number of cases
Associated with lymph node
metastasis
MEC 15 4 (high grade variant)
ADCC 14 4 (2 of solid type and 2 of cribriform type)
EMC 3 -
SDC 5 2
MP A 5 -
PLGA 6 -
ACC 5 1
Total 53 11
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superior sensitivity of the MCM proteins over the stan-
dard proliferation markers such as Ki-67 resides in the
fact that MCMs identify not only cycling cells, but also
non-cycling cells with proliferative potential [35].
High grade MEC is characterized by decreased maspin
expression. Loss or decreased expression of maspin indi-
cates loss of its role in inhibition of tumor invasion,
metastasis and angiogenesis [3]. Evidence of both nuclear
and cytoplasmic maspin expression was observed in low
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Figure 1 Maspin expression patterns in salivary gland carcinomas. a: low grade MECx200. b: ADCCx200. c: EMCx200. d: SDCx200. e:
MPAx200. f: PLGAx200. g: ACCx100.
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localization has an influence on its role as tumor sup-
p r e s s o rg e n e[ 5 ] .S o o de ta l[ 3 6 ]d e m o n s t r a t e dt h a t
m i x e dn u c l e a ra n dc y t o p l a s m ic maspin localization in
ovarian cancer is indicative of a more benign lesion than
neoplasms with cytoplasmic expression only, suggesting
an important tumor-suppressive role for nuclear maspin.
This maspin nuclear localization pattern had been seen
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Figure 2 MCM2 expression patterns in salivary gland carcinomas. a: high grade MECx200. b: ADCCx200. c: EMCx400. d: SDCx200. e:
MPAx200. f: PLGAx200. g: ACCx400.
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carcinoma and pancreatic cancer, where predominantly
nuclear maspin is associated with favorable morphologic
features [11,24].
The high grade MEC cases showed a marked increase of
MCM2 expression when compared to the low grade cases,
which was also in agreement with Vargas et al [34]. This
might be explained by the fact that in cancer, differen-
tiated neoplastic cells tend to grow and spread at a slower
rate than undifferentiated or poorly differentiated cells,
which lack the structure and function of normal cells and
grow uncontrollably [37]. It was stated that withdrawal of
cells from the cell cycle into differentiated state is coupled
with downregulation of MCM2 expression [31,35].
In ADCC, cases with solid pattern were maspin immu-
nonegative, which was in agreement with Navarro et al
[15] and indicates the aggressive behavior of this pattern.
Maass et al [38] stated that maspin is lost in the metastatic
cells, and Shwarz et al [3] reported in his study that in
intermediate grade tumours (ADCC, MEC, carcinoma
expleomorphic adenoma) loss of maspin expression,
mainly localized to the nucleus, was associated with lymph
node metastases.
Myoepithelial cells in ADCC were maspin immunonega-
tive. This result was in agreement with Navarro et al [15].
Normally maspin is expressed in high amounts in myoe-
pithelial cells and it was suggested that maspin can be
used as a myoepithelial cell marker [39]. Thus, loss of
maspin in this cell might indicate the role of myoepithelial
cells in malignant transformation and histogenesis of this
neoplasm [40].
Adenoid cystic carcinoma demonstrated high value of
MCM2 expression; this finding gives an impression of
the high proliferative power of ADCC. This result was
consistent with previous study denoting that ADCC is a
highly proliferative salivary gland neoplasm [34].
Myoepithelial carcinoma showed the smallest value of
maspin expression, and high value of MCM2 expression.
These values might indicate the aggressive behavior of
this neoplasm. The knowledge of myoepithelial carci-
noma behavior and the optimal line of management are
deficient, possibly due to its rare occurrence and the lack
of comprehensive reports of large case series [41]. How-
ever, some authors describe myoepithelial carcinoma by
infiltrative growth and potential metastasis [2,41,42].
Salivary duct carcinoma revealed the highest value of
MCM2 expression and reduced maspin expression; this
finding confirms the high grade behavior of this tumor [43].
Malignant pleomorphic adenoma possessed the highest
value of maspin expression and low MCM2 expression,
this is in accordance with Umekita et al [44] who observed
that high maspin expression in breast carcinoma was asso-
ciated with poor prognosis, and this was explained by
genetic alteration at the maspin gene locus contributing to
the loss of tumor suppressing function of the maspin pro-
tein. Values of maspin and MCM2 expression in PLGA
and ACC reflected low grade nature of these tumors
which are characterized by a low metastatic potential and
a high survival rate [2].
The differential diagnosis of both ADCC and PLGA is of
a great interest as both share common histopathological
features and may cause diagnostic difficulty particularly in
small biopsies [1]. Our data demonstrated that ADCC has
a higher proliferation power compared to PLGA as deter-
mined by MCM2 immunostaining. This result was in con-
formity with Vargas et al [34] who support the idea that
proliferation markers can be used to differentiate border-
line cases.
No significant correlation between maspin expression
and lymph node metastasis was found in this study. This
finding disagrees with Schwarz et al [3] who reported that
lack of maspin expression was significantly correlated with
Table 2 ANOVA for maspin
ANOVA
MEAN AF
Sum of Squares df Mean Square F Sig.
Between Groups 3682.051 2 1841.026 683.744 .000
Within Groups 80.777 30 2.693
Total 3762.828 32
Table 3 ANOVA for MCM2
ANOVA
MEAN AF
Sum of Squares df Mean Square F Sig.
Between Groups 713.006 2 356.503 39.753 .000
Within Groups 286.978 32 8.968
Total 999.984 34
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small sample size used in this study in which only 11 cases
were associated with positive lymph node metastasis.
Also, there was no significant correlation between
MCM2 expression and positive lymph node metastasis.
This result was in agreement with Vargas et al [34] and
was dissimilar to Guzinska-Ustymowiczi et al study [45]
in which MCM2 over expression was associated with
lymph node metastasis.
Maspin and MCM2 are important markers of biological
behavior in salivary gland carcinomas. Further study with
large sample size is required to clarify the correlation
between maspin and MCM2 expression and lymph node
metastasis.
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